目的 观察胸腺肽α-1辅助吸入糖皮质激素(inhale corticosteroids，ICS)/长效β2受体激动剂(long actiong β2-agonist，LABA)治疗对哮喘-慢性阻塞性肺疾病重叠综合征(asthma-chronic obstructive pulmonary disease overlap syndrome，ACOS)患者肺功能和免疫功能的影响。方法 选取75例ACOS患者，用随机数字表法分为对照组(ICS/LABA治疗)和辅助治疗组(胸腺肽α-1辅助ICS/LABA治疗)，比较2组治疗前后急性加重次数、慢性阻塞性肺疾病自我评估(COPD assessment test，CAT)评分、哮喘控制测试(asthma control test，ACT)评分、肺功能[第 1 秒用力呼气容积(forced expirotovy volume in one second，FEV1)、FEV1/用力肺活量(forced vital capacity，FVC)值和呼气峰流速(peak expiratory flow，PEF)]、免疫功能(CD3+、CD4+和 CD4+/CD8+值)、疗效及不良反应发生情况。结果 辅助治疗组的总有效率(97。37％)显著高于对照组(78。38％)，P＜0。05;辅助治疗组急性加重次数、CAT评分明显低于对照组(P＜0。05)，ACT评分明显高于对照组(P＜0。05);辅助治疗组FEV1、FEV1/FVC值及PEF明显高于对照组(P＜0。05);辅助治疗组CD3+、CD4+及CD4+/CD8+值均显著高于对照组(P＜0。05);2组不良反应总发生率比较差异无统计学意义(P＞0。05)。结论 胸腺肽α-1辅助ICS/LABA治疗ACOS可有效提高患者的免疫功能，促进肺功能恢复，且安全性好。
Therapeutic effect of thymosin α-1 assisted inhaled corticosteroid/long-acting β2 agonist treatment on asthma-chronic obstructive pulmonary syndrome overlap syndrome
Objective To observe the effect of thymosin α-1 assisted inhaled corticosteroid(ICS)/long-acting β2 agonist(LABA)treatment on pulmonary function and immune function in patients with asthma-chronic obstructive pulmonary syndrome(COPD)overlap syndrome(ACOS).Methods A total of 75 patients with ACOS were divided into control group(ICS/LABA treatment)and adjuvant treatment group(thymosin α-1 assisted ICS/LABA treatment)by random number table method.The number of acute exacerbations,COPD assessment test(CAT)scores,Asthma Control Test(ACT)scores,pulmonary function[forced expiratory volume in one second(FEV1),FEV1/forced vital capacity(FVC)and peak expiratory flow(PEF)],immune function(CD3+,CD4+and CD4+/CD8+),therapeutic effect,and adverse reactions were compared between the 2 groups.Results The total effective rate in the auxiliary treatment group(97.37％)was significantly higher than that in the control group(78.38％)(P＜0.05).The number of acute exacerbations and CAT score in the auxiliary treatment group were significantly lower than those in the control group(P＜0.05),and ACT score was significantly higher than that in the control group(P＜0.05).FEV1,FEV1/FVC and PEF in the auxiliary treatment group were significantly higher than those in the control group(P＜0.05).CD3+,CD4+and CD4+/CD8+in the auxiliary treatment group were significantly higher than those in the control group(P＜0.05).There was no statistically significant difference in the total incidence rate of adverse reactions between the 2 groups(P＞0.05).Conclusion Thymosin α-assisted ICS/LABA treatment for ACOS can effectively improve the patients'immune function and promote the recovery of pulmonary function,with good safety.
thymosin α-1corticosteroidlong-actingβ2 agonistasthma-chronic obstructive pulmonary disease overlap syndromepulmonary functionimmune function
NETL
NSTL
万方数据
